IRCT20200623047902N28尚未招募Unknown
Bioequivalence study of Rivaroxaban 20mg tablet manufactured by Darou Darman Arang versus originator brand in healthy volunteers in the fasted condition
Darou Darman Arang company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Rivaroxaban
研究者
相似试验
招募中
不适用
Bioequivalence study of Rivaroxaban 20 mg tabletBioequivalence study of Rivaroxaban 20 mg tablet (Tehran Darou) versus Xalerto® 20 mg (Bayer) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N4tehran darou Pharmaceutical Company24
尚未招募
不适用
A bioequivalence study of Rivaroxaban 20 mg tab compared to Xarelto 20 mg tab manufactured by Bayer in 24 healthy volunteers under fasting conditioIRCT20220209053979N1Pars Darou24
尚未招募
不适用
In-vivo Bioequivalence Test of Rivaroxaban® tablet with brand drugs (Xarelto® Bayer, Germany).IRCT20200105046010N27Jaber Ibn Hayyan Pharmaceutical Company24
已完成
1 期
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537405Bayer40
已完成
1 期
Bioequivalence Study of RivaroxabanEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537457Bayer40